B · Normal
[Eli Lilly’s sales of Mounjaro increased by 65% in the third quarter and Zepbound increased by 49%] On October 29, Eli Lilly’s third quarter global sales of diabetes drug Mounjaro were US$10.723 billion, a year-on-year increase of 65%; sales of the weight loss drug Zepbound were US$5.352 billion, a year-on-year increase of 49%. Among them, Mounjaro’s sales in the US market were approximately US$5 billion, a year-on-year increase of 41%; Zepbound’s US market sales were approximately US$5.3 billion, a year-on-year increase of 48%.
Comments